National Pension Service Has $465.74 Million Stock Position in Amgen Inc. $AMGN

National Pension Service increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,286,149 shares of the medical research company’s stock after acquiring an additional 12,260 shares during the period. National Pension Service’s holdings in Amgen were worth $465,740,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AMGN. Pinnacle Wealth Management Advisory Group LLC grew its stake in Amgen by 5.4% in the second quarter. Pinnacle Wealth Management Advisory Group LLC now owns 14,622 shares of the medical research company’s stock valued at $5,295,000 after purchasing an additional 746 shares in the last quarter. Integrated Wealth Concepts LLC raised its stake in shares of Amgen by 2.3% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 24,183 shares of the medical research company’s stock worth $8,757,000 after purchasing an additional 541 shares in the last quarter. Community Bank N.A. raised its stake in shares of Amgen by 1.3% during the 2nd quarter. Community Bank N.A. now owns 16,708 shares of the medical research company’s stock worth $6,050,000 after purchasing an additional 216 shares in the last quarter. RFG Advisory LLC boosted its holdings in shares of Amgen by 2.9% in the 2nd quarter. RFG Advisory LLC now owns 14,031 shares of the medical research company’s stock valued at $5,081,000 after buying an additional 399 shares during the last quarter. Finally, IFP Advisors Inc boosted its holdings in shares of Amgen by 8.5% in the 2nd quarter. IFP Advisors Inc now owns 8,216 shares of the medical research company’s stock valued at $2,975,000 after buying an additional 643 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AMGN. Piper Sandler boosted their target price on shares of Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Scotiabank increased their price target on shares of Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Wells Fargo & Company lifted their price objective on shares of Amgen from $400.00 to $435.00 and gave the company an “equal weight” rating in a research report on Friday, September 4th. Morgan Stanley restated an “overweight” rating and set a $362.00 price objective on shares of Amgen in a research note on Wednesday, August 19th. Finally, HSBC cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $381.68.

Amgen Stock Down 0.5%

AMGN opened at $391.27 on Thursday. The stock’s fifty day simple moving average is $400.14 and its 200 day simple moving average is $367.79. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $447.03. The stock has a market cap of $211.53 billion, a PE ratio of 24.32, a price-to-earnings-growth ratio of 2.83 and a beta of 0.43. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the previous year, the business posted $6.02 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts expect that Amgen Inc. will post 22.97 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insider Activity

In related news, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 in the last ninety days. 0.85% of the stock is currently owned by insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported that the Phase 3 DeLLphi-305 trial met its primary endpoint. Imdelltra combined with Imfinzi significantly improved overall survival in first-line extensive-stage small-cell lung cancer and also met progression-free survival and response-rate endpoints, strengthening the commercial outlook for Imdelltra. Amgen Imdelltra Phase 3 results
• Positive Sentiment: William Blair maintained a Buy rating, citing the Imdelltra Phase 3 success as support for Amgen’s pipeline and investment case. Piper Sandler also reaffirmed its Buy rating. Imdelltra analyst rating
• Neutral Sentiment: Amgen is scheduled to present at the Morgan Stanley Global Healthcare Conference, potentially providing updates on olpasiran, Imdelltra and broader pipeline priorities. Amgen Morgan Stanley conference presentation
• Neutral Sentiment: Analyst views remain mixed: Wells Fargo reiterated Hold, while Cantor Fitzgerald maintained Neutral with a $400 price target, suggesting limited near-term upside from recent levels. Wells Fargo Amgen rating
• Negative Sentiment: Novartis’ Phase 3 pelacarsen trial failed to reduce cardiovascular events despite lowering Lp(a), raising doubts about whether the biomarker translates into clinical benefits. Investors consequently questioned the prospects for Amgen’s olpasiran, which remains in a large late-stage heart-outcomes study. Novartis cholesterol drug setback
• Negative Sentiment: BMO downgraded Amgen to Market Perform from Outperform, citing a less favorable risk-reward balance and limited near-term upside. Broader market pressure from higher oil prices, inflation concerns and interest-rate uncertainty has added to selling pressure. BMO Amgen downgrade

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.